PubRank

Steven W Yancey

Author PubWeight™ 36.42‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006 8.43
2 Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med 2014 4.95
3 Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 2014 3.50
4 Salmeterol response is not affected by beta2-adrenergic receptor genotype in subjects with persistent asthma. J Allergy Clin Immunol 2006 2.49
5 Beta2-receptor polymorphisms in patients receiving salmeterol with or without fluticasone propionate. Am J Respir Crit Care Med 2009 2.27
6 Fluticasone propionate nasal spray is superior to montelukast for allergic rhinitis while neither affects overall asthma control. Chest 2005 1.66
7 Steroid-sparing effects of fluticasone propionate 100 microg and salmeterol 50 microg administered twice daily in a single product in patients previously controlled with fluticasone propionate 250 microg administered twice daily. J Allergy Clin Immunol 2003 1.54
8 Control of airway inflammation maintained at a lower steroid dose with 100/50 microg of fluticasone propionate/salmeterol. J Allergy Clin Immunol 2006 1.44
9 Blood eosinophil count is a useful biomarker to identify patients with severe eosinophilic asthma. Ann Am Thorac Soc 2014 1.00
10 Body mass index and response to asthma therapy: fluticasone propionate/salmeterol versus montelukast. J Asthma 2010 0.95
11 Comparative effect of body mass index on response to asthma controller therapy. Allergy Asthma Proc 2010 0.88
12 Effect of increased body mass index on asthma risk, impairment and response to asthma controller therapy in African Americans. Curr Med Res Opin 2010 0.86
13 Adding montelukast to fluticasone propionate/salmeterol for control of asthma and seasonal allergic rhinitis. Allergy Asthma Proc 2010 0.83
14 Fluticasone propionate/salmeterol and exercise-induced asthma in children with persistent asthma. Pediatr Pulmonol 2009 0.83
15 Effect of fluticasone propionate and salmeterol in a single device, fluticasone propionate, and montelukast on overall asthma control, exacerbations, and costs. Ann Allergy Asthma Immunol 2004 0.80
16 Montelukast added to fluticasone propionate does not alter inflammation or outcomes. Respir Med 2010 0.76
17 Efficacy and safety of fluticasone propionate/salmeterol 250/50 mcg Diskus administered once daily. Respir Med 2008 0.76
18 No association of catastrophic events with Advair. Am J Med 2010 0.75
19 Meeting the obligation to balance bioethics and clinical trial design in asthma. Am J Respir Crit Care Med 2010 0.75
20 Asthma control differences between inhaled corticosteroids likely related to differences in patient severity. J Allergy Clin Immunol 2011 0.75
21 Evaluation of fluticasone propionate and fluticasone propionate/salmeterol combination on exercise in pediatric and adolescent patients with asthma. Open Respir Med J 2011 0.75